Granite Bay, Calif. – October 01, 2026 -- GMP Labeling Inc. is marking Manufacturing Day 2026 by positioning its nearly 40-year domestic production history as a hedge against global supply chain disruption for pharmaceutical and biotechnology manufacturers. The California-based company, founded in 1987, manufactures quality control labels, sample identification tags, and equipment status markers used across regulated production lines.
Label failures can halt regulated production lines
Material inconsistencies or shipping delays in compliance labeling can interrupt manufacturing workflows, complicate federal audits, and compromise quality records, according to the company. Robin Kalsbeek, General Manager of GMP Labeling, said a label functions as a critical element of traceability and compliance rather than a minor supply item in biotechnology and medical manufacturing settings.
Domestic manufacturing model targets four operational risk points
GMP Labeling cites four specific advantages of its U.S.-based production for life sciences clients. Stock quality control labels are kept available for rapid dispatch to prevent bottlenecks. Revision-controlled development and lot segregation practices are used to maintain material consistency across long-term projects. The company's ISO 9001-certified quality management system is open for customer review to support supplier evaluation programs. Label engineering is designed to withstand cryogenic storage, autoclave cycles, and xylene exposure.
Company positions U.S. footprint against international logistics volatility
GMP Labeling has maintained continuous U.S. manufacturing operations since 1987, which it presents as an alternative to international suppliers exposed to shipping and logistics disruptions. The company's product catalog extends beyond core compliance labels to facility signage, barcode printers, and custom identification solutions built for cleanroom-compatible applications.